Martingale Asset Management’s Cogent Biosciences COGT Stock Holding History

Martingale Asset Management’s Portfolio COGT Stock Details COGT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$350K	Buy	+9,039	New	+$316K	0.01%	725

Other funds holding COGT

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Jupiter Topco New York $245B AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Martingale Asset Management's COGT Position: Q2 2026 in Review

Martingale Asset Management opened a new position in Cogent Biosciences (COGT) in Q2 2026: 9,039 shares worth $350K. The stake represents 0.01% of the portfolio and ranks #725 among its holdings.

322 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

Martingale Asset Management held 9,039 shares of Cogent Biosciences worth $350K as of Q2 2026.
Cogent Biosciences was a new Martingale Asset Management position in Q2 2026.
Cogent Biosciences made up 0.01% of Martingale Asset Management's portfolio in Q2 2026, its #725 holding.
322 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on Martingale Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.